M. CABELLO BORNES (1), A. MORENO PERALTA (2), E. MONTORO PAVON(3) and M. RODRÍGUEZ (4) J. STEINBRUNN(5) (1) U.G.C. Nurse, Arcos de la frontera, Member of Gneaupp, (2) U.G.C. Nurse Arcos de la Frontera, (3) U.G.C. Nurse, Livera, (4) U.G.C. Nurse Ubrique, Spain. (5)Laboratoires Urgo, Chenôve, France.

1. TREATMENT WITH A TLC-NOSF DRESSING*
M. CABELLO BORNES (1), A. MORENO PERALTA (2), E. MONTORO PAVON(3)
and M. RODRÍGUEZ (4)
J. STEINBRUNN(5)
(1) U.G.C. Nurse, Arcos de la frontera, Member of Gneaupp,
(2) U.G.C. Nurse Arcos de la Frontera, (3) U.G.C. Nurse, Livera, (4) U.G.C. Nurse Ubrique, Spain.
(5)Laboratoires Urgo, Chenôve, France.
*Brand name: the TLC-NOSF dressing is UrgoStart®

2. INTRODUCTION
74 year-old male patient, with history of Diabetes Mellitus and Arterial Hypertension. Has
an itinerant lifestyle and has recently undergone catheterism.
The patient has a normal nutritional status.
He is independent, but with some limitations in terms of activities in daily life.
He was admitted to our centre for us to administer treatments.
He presented a lesion on the anterior surface of the lower third of the right leg.
At the time of inclusion in the study he had granulation tissue measuring approximately
8x3 cm.

3. METHODOLOGY
Initially treatments were carried out aimed at cleaning the unviable necrotic tissue that was
present using hydro-desloughing dressing.
This was followed by preventive elimination of bacteria using an alginate dressing .
When the wound was clean, with no signs of infection, we decided to include him in the
study and began by applying metalloproteinase-inhibiting dressings*.
Cleaning of the lesion took approximately five weeks.
Because the level of exudate from the wound was moderate we scheduled the treatments
so that they were given twice a week.
From the time we commenced treatment with the dressings the healing course was
spectacular, with total closure of the wound in four weeks (eight treatments), and with
excellent aesthetic results.
*Brand name: the metalloproteinase-inhibiting dressing is UrgoStart®

4. Week 0
PICTURES
Week 6

5. This clinical case was another case in which we monitored use of this product , the results
being similar to those described in over 90% of cases.
The use of metalloproteinase-inhibiting dressings* promotes the early closure of the
wounds with optimum aesthetic results.
This leads to a shorter nursing time and fewer visits by patients to the centres.
The slight increase in cost, in terms of the unit price of the dressings, is compensated for
by the above-mentioned reduction in nursing time required for the wounds to heal.
The cost effectiveness of this product is therefore more than favourable.
Cases where the development was not initially satisfactory were due to incorrect
elimination of bacteria from the wound.
In these cases a rapid increase in infection took place.
Once this was controlled we began using the dressings again, with the results described.
Summing up, the metalloproteinase-inhibiting dressings* are a valuable tool to
consider at the time of treatment of the wounds since they are already significantly
reducing the nursing times for wound care.
CONCLUSION
*Brand name: the metalloproteinase-inhibiting dressing is UrgoStart®